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Purpose: The purpose of this study was to examine,
using a US electronic medical records (EMR) data-
base, the clinical characteristics and real-world
treatment sequences in men with advanced prostate
cancer who initiated treatment with abiraterone
acetate or enzalutamide.
Methods: This retrospective, observational study
evaluated adult male patients with a diagnosis
of prostate cancer (International Classiﬁcation of
Diseases, Ninth Revision, Clinical Modiﬁcation code
185) in the EMR database between July 1, 2011, and
March 31, 2014, who had initiated ﬁrst-line treatment
with abiraterone acetate or enzalutamide between
September 1, 2012, and March 31, 2014. The ﬁrst
record for a patient initiating abiraterone acetate or
enzalutamide was the index date. Patients had 6
months of pre-index medical record history and a
variable length follow-up period, extending from the
index date to the end of medical record data avail-
ability or date of the end of the study (March 31,
2014). The sequence of ﬁrst- and second-line therapies
for advanced prostate cancer therapy was reported.
Findings: A total of 809 patients met study inclu-
sion and exclusion criteria. This study found that the
majority of patients who initiated treatment with
either abiraterone acetate or enzalutamide between
September 1, 2012, and March 31, 2014, received a
single line of therapy (72%); abiraterone acetate was
the most common ﬁrst-line treatment (74% of ﬁrst-
line patients). A subset of patients treated ﬁrst-line
with either abiraterone acetate or enzalutamide were
transitioned to an oral second-line agent (17% of
ﬁrst-line abiraterone acetate–treated patients transi-
tioned to second-line enzalutamide, and 16% of ﬁrst-
line enzalutamide-treated patients transitioned toAugust 2016second-line abiraterone acetate). Chemotherapy with
docetaxel was also a commonly observed second-line
treatment selection, occurring in 8% of ﬁrst-line
abiraterone acetate–treated patients and in 7% of
ﬁrst-line enzalutamide-treated patients.
Implications: This EMR study is among the ﬁrst to
present evidence of US physician practice prescribing
patterns regarding initiation of oral antineoplastic
agents and use of subsequent therapies in patients
with advanced prostate cancer. (Clin Ther.
2016;38:1817–1824) & 2016 The Authors. Published
by Elsevier HS Journals, Inc.
Key words: abiraterone acetate, enzalutamide,
metastatic castration-resistant prostate cancer.INTRODUCTION
After skin cancer, prostate cancer is the most common
cancer diagnosed among men in the United States.1
Approximately 220,000 incident cases of prostate
cancer were diagnosed in 2015, which is decreasing
over time due to changes in screening for prostate
cancer with prostate-speciﬁc antigen (PSA).1 In male
patients, metastatic, castration-resistant prostate
cancer (mCRPC) is the second deadliest cancer after
lung cancer, resulting in 30,000 deaths per year in
the United States.1817
Clinical TherapeuticsAlthough there is no cure for mCRPC, docetaxel, a
member of the taxane class, has historically been the
standard of care for treating advanced prostate
cancer. A clinical trial in patients with mCRPC
reported a 2.4-month improvement in overall survival
for docetaxel in combination with prednisone, com-
pared with mitoxantrone plus prednisone.2 In the past
5 years, several additional treatment options have
emerged that offer novel mechanisms of action, side
effect proﬁles, modes of administration, and survival
beneﬁts to patients with mCRPC.3–6 Sipuleucel-T, ﬁrst
in the class of autologous cellular immunotherapies
indicated for prostate cancer, involves harvesting
and priming the patient’s CD54þ cells with prostatic
antigen phosphatase-granulocyte macrophage colony-
stimulating factor and infusion of these cells in three
60-minute infusions at 2-week intervals (over a total
of 6 weeks). In 2 randomized controlled trials of men
with asymptomatic or minimally symptomatic
mCRPC, sipuleucel-T treatment led to 4.5 and 4.1
months of improvement in overall survival versus
placebo, respectively.7,8 Abiraterone acetate, given
orally in combination with prednisone, was the ﬁrst
androgen biosynthesis inhibitor approved by the
US Food and Drug Administration for the treatment
of mCRPC. Abiraterone acetate acts by inhibiting
cytochrome p450 17A1, an enzyme in the androgen
synthesis pathway, and blocks androgen production
at the testes, adrenal, and tumor.9,10 Phase III studies
in men with asymptomatic or mildly symptomatic
mCRPC found a 4.4- month improvement in overall
survival for abiraterone acetate plus prednisone versus
prednisone alone.11 Another oral agent, enzalutamide,
inhibits the androgen receptor, preventing androgen
signaling.9,10 Phase III studies in men with
asymptomatic or mildly symptomatic chemo-
therapy-experienced mCRPC exhibited a 4-month
improvement in overall survival for enzalutamide
versus placebo.12 Both abiraterone acetate and
enzalutamide increased overall survival in patients
with mCRPC in the prechemotherapy setting.13,14
Another agent, cabazitaxel, administered intrave-
nously, exhibited a median overall survival beneﬁt of
2.4 months compared with mitoxantrone alone.15
Because of this rapid expansion in the number of
mCRPC treatment options, few studies have inves-
tigated how clinicians are selecting treatments in
clinical practice, particularly orally administered
therapies.16 The aim of the current study was to1818describe patient characteristics and treatment
sequences in patients with mCRPC recorded in an
electronic medical records (EMR) database drawn
from US community oncology practices.MATERIALS AND METHODS
Data Source
The Truven Health MarketScan Oncology EMR
Database was used to conduct this study. The oncol-
ogy EMR database contains medical record data for
4500,000 patients actively seen in 4100 community
oncology practices throughout the United States at
any time from July 2011 through March 2014, as well
as all historical data for patients captured during this
period. The database contains information on patient
demographic characteristics, diagnoses, cancer stage,
histology, treatments, outcomes, and other clinical
information contained in the digital ﬁelds of the
EMR. All geographic regions of the United States
are represented, with 38% of patients coming from
the South, 25% from the Northeast, 20% from the
West, and 17% from the North Central region. All
age groups are included; 53% of the patients are aged
Z65 years. The data contained in these databases
were processed by statistical de-identiﬁcation and
were certiﬁed to satisfy the conditions set forth in
Sections 164.514 (a)-(b)(1)ii of the Health Insurance
Portability and Accountability Act. Institutional re-
view board approval and written informed consent
were therefore not required for this study.
Subject Selection and Follow-up
Patients were retrospectively selected for the study
and had a diagnosis of prostate cancer, as indicated by
International Classiﬁcation of Diseases, Ninth Revi-
sion, Clinical Modiﬁcation code 185 in the medical
record at any time between July 1, 2011, and March
31, 2014, and had their ﬁrst prescription for abirater-
one acetate or enzalutamide between September 1,
2012, and March 31, 2014; this time coincides with a
period when both medications were commercially
available in the Unites States. The ﬁrst EMR record
for a patient initiating abiraterone acetate or enzalu-
tamide between September 1, 2012, and March 31,
2014, was designated as the index date. To ensure
patients were newly initiating treatment, patients were
required to have 6 months of pre-index medical record
history and to have no abiraterone acetate orVolume 38 Number 8
E. Malangone-Monaco et al.enzalutamide treatment in the 6-month pre-index
period. Study patients were excluded if they were
agedo18 years on the index date, had other cancer as
their ﬁrst occurring primary cancer, had invalid
medical record data, or had evidence of concurrent
use of abiraterone acetate or enzalutamide on the
index date. The follow-up period varied in length and
extended from the index date to the last date of
medical record data availability in the oncology
EMR database or to the date of the end of the study
(March 31, 2014), whichever occurred earliest.
Outcomes
A line of therapy was deﬁned as the period from the
ﬁrst to the last medical record indicating a study
medication of interest before a switch to a subsequent
line of therapy or the end of the study period.
Individual ﬂags were created to identify subsequent
lines of therapy for the following medications of inte-
rest, using all variations in generic and brand name to
identify each drug: abiraterone acetate, enzalutamide,
docetaxel, cabazitaxel, and sipuleucel-T. Treatment
sequences ranging from ﬁrst to third lines of treatment
were reported. For example, a patient who initiated
abiraterone acetate and then switched to enzalutamide
was categorized as abiraterone acetate followed by
enzalutamide. A patient who initiated abiraterone
acetate and then switched to enzalutamide and thenTable I. Study attrition.
Inclusion and Exclusion Criteria
Patients Z18 years of age with prostate cancer between
July 1, 2011, and March 31, 2014 and abiraterone acet
enzalutamide treatment between September 1, 2012, a
Evidence of prostate cancer as ﬁrst occurring primary can
No abiraterone acetate or enzalutamide treatment in the
Medical record history with valid study start and end dat
No evidence of any other primary cancers
At least 180 days of preindex medical record history
No evidence of concurrent use of abiraterone acetate and
enzalutamide on index date or during the line of thera
Final patient count
First-line abiraterone acetate
First-line enzalutamide
August 2016switched back to abiraterone acetate was categorized as
abiraterone acetate followed by enzalutamide followed
by abiraterone acetate.
Concurrent treatment with hormone therapy
(luteinizing hormone-releasing hormone [LHRH]
agonists, LHRH antagonists, antiandrogens, and
diethylstilbestrol), corticosteroids, and other biologic
and chemotherapy treatments was identiﬁed during
the ﬁrst line of therapy.
Patient Demographic and Clinical Characteristics
Patient demographic and clinical characteristics
were collected to describe the patient population.
Demographic characteristics were measured on the
index date and included patient age in years, US
Census Bureau geographic region of residence, and
insurance plan type. Clinical characteristics were
measured during the pre-index period from available
EMR data ﬁelds, including disease stage, metastasis
status, sites of metastasis, indicators for previous
prostate cancer procedures (eg, surgical castration,
radiation therapy), and previous prostate cancer treat-
ments (hormone therapies [LHRH agonists, LHRH
antagonists, antiandrogens, and diethylstilbestrol],
corticosteroids, and other biologic and chemotherapy
treatments). PSA scores were measured in the pre-
index period by using the PSA test result that was
most proximate to the index date.Patients
No. %
ate or
nd March 31, 2014
1586 100.0
cer type 1518 95.7
preindex period 1433 90.4
es 1379 86.9
1338 84.4
830 52.3
py
809 51.0
809 51.0
602 74.4
207 25.6
1819
Table II. Demographic and baseline clinical characteristics. Unless otherwise indicated, values are given
as number (%).
Characteristic
First-Line Abiraterone
Acetate (n ¼ 602)
First-Line
Enzalutamide (n ¼ 207)
Age, mean (SD), y 75.2 (9.7) 75.2 (10.3)
Age group
46–55 y 17 (2.8) 8 (3.9)
56–65 y 85 (14.1) 29 (14.0)
66–75 y 201 (33.4) 66 (31.9)
76–84 y 181 (30.1) 68 (32.9)
Z85 y 118 (19.6) 36 (17.4)
Geographic region
Northeast 129 (21.4) 36 (17.4)
North Central 71 (11.8) 26 (12.6)
South 257 (42.7) 100 (48.3)
West 139 (23.1) 45 (21.7)
Unknown 6 (1.0) 0
Disease stage
Early stage (stage I/II) 2 (0.3) 0
Stage III 3 (0.5) 2 (1.0)
Stage IV 402 (66.8) 152 (73.4)
Unknown/missing 195 (32.4) 53 (25.6)
Metastatic sites
Bone 315 (78.4) 124 (81.6)
Lung 6 (1.5) 0
Lymph nodes 41 (10.2) 24 (15.8)
Other 13 (3.2) 7 (4.6)
Unknown/missing 61 (15.2) 18 (11.8)
PSA test result category
Normal (0–4 ng/mL) 65 (10.8) 23 (11.1)
Elevated (44 ng/mL) 460 (76.4) 155 (74.9)
Unknown/missing 77 (12.8) 29 (14.0)
Surgical castration 3 (0.5) 2 (1.0)
Preindex medications
LHRH agonists 250 (41.5) 75 (36.2)
LHRH antagonists 10 (1.7) 6 (2.9)
Antiandrogens 236 (39.2) 62 (30.0)
Diethylstilbestrol 1 (0.2) 0
Corticosteroids 234 (38.9) 97 (46.9)
Chemotherapy* 155 (25.7) 92 (44.4)
Docetaxel 105 (17.4) 72 (34.8)
Cabazitaxel 53 (8.8) 26 (12.6)
Sipuleucel-T 12 (2.0) 5 (2.4)
LHRH ¼ luteinizing hormone-releasing hormone; PSA ¼ prostate-speciﬁc antigen.
*In addition to agents listed here, includes mitoxantrone, estramustine, doxorubicin, etoposide, vinblastine, paclitaxel, and
vinorelbine.
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E. Malangone-Monaco et al.Statistical Analyses
Summary statistics were used to describe the
demographic characteristics, baseline clinical charac-
teristics, and study outcomes. No formal statistical
tests were performed to compare data between
mCRPC treatment groups.0
20
Single Line of Therapy 
(n = 580)
Two Lines of Therapy 
(n = 173)
≥3 Lines of Therapy  
(n = 56)
Pe
r
Figure 1. Distribution of first-line, second-line, and
subsequent lines of therapy.RESULTS
A total of 1586 patients were identiﬁed with a
prostate cancer diagnosis and an order for either
abiraterone acetate or enzalutamide. Fifty-one percent
(n ¼ 809) met all study inclusion and exclusion
criteria as shown in Table I.
Patient Clinical Characteristics
Patients treated with ﬁrst-line abiraterone acetate
or enzalutamide had a mean age of 75 years. A
slightly higher proportion of ﬁrst-line enzalutamide-
treated patients were observed in the Southern region
(Table II). The patient groups had similar disease stage
at the index date, with the majority of patients in both
groups having some notation of stage IV disease (67%
and 73% of the abiraterone acetate and enzalutamide
groups, respectively). The primary metastatic site
noted was bone. Approximately three quarters of
each group had elevated PSA scores in the 6-month
pre-index period. Approximately 50% to 60% of
patients had a record of previous treatment with
LHRH agonists, LHRH antagonists, antiandrogens,
or other hormonal agents. Preindex corticosteroid use
was observed in a slightly higher proportion of
patients with ﬁrst-line enzalutamide (47%) compared
with patients with ﬁrst-line abiraterone acetate (39%).
Similarly, a higher proportion of ﬁrst-line enzaluta-
mide-treated patients had pre-index docetaxel exposure
compared with ﬁrst-line abiraterone acetate–treated
patients (35% and 17% of the enzalutamide and
abiraterone acetate groups, respectively).
Observed Treatment Sequences
Seventy-two percent of patients in this study re-
ceived 1 line of therapy (Figure 1). The most
commonly observed ﬁrst-line therapy was abiraterone
acetate (74% of ﬁrst-line patients). First-line enzalu-
tamide was observed in 26% of patients. Use
of a second-line agent was observed in 28%
of patients overall (Table III). Among ﬁrst-line
abiraterone acetate–treated patients, 27% continuedAugust 2016to a second-line therapy. Among ﬁrst-line enzaluta-
mide-treated patients, 31% continued to a second-line
therapy. An oral medication was observed commonly
for a second-line treatment; 17% of ﬁrst-line
abiraterone acetate–treated patients transitioned to
second-line enzalutamide, and 16% of ﬁrst-line
enzalutamide-treated patients received second-line
abiraterone acetate. Chemotherapy with docetaxel
was also commonly observed as a second-line treat-
ment selection, occurring in 8% of ﬁrst-line abirater-
one acetate–treated patients and in 7% of ﬁrst-line
enzalutamide-treated patients. Approximately 6% of
ﬁrst-line enzalutamide-treated patients (10 of 207
patients) received cabazitaxel as a second-line agent,
and 2% of abiraterone acetate–treated patients re-
ceived cabazitaxel as a second-line agent (10 of 602).
Concurrent medication use was higher among
abiraterone acetate–treated patients, with slightly
greater use of concurrent hormone therapy (31% vs
25% for abiraterone acetate vs enzalutamide,
respectively). Likewise, concurrent corticosteroid use
was observed in a higher proportion of abiraterone
acetate–treated patients (76%) compared with
enzalutamide-treated patients (13%) (Figure 2).
Most patients in the 2 groups did not receive
concurrent chemotherapy (0.5% vs 2% for
abiraterone acetate vs enzalutamide, respectively).DISCUSSION
To the best of our knowledge this study is among the
ﬁrst to report real-world treatment sequencing of oral
antineoplastic agents for advanced prostate cancer.
This retrospective EMR study found that the majority1821
Table III. First to second line of therapy.
First to Second-Line Treatment Sequence
All First-Line Patients (N ¼ 809)
No. %
Abiraterone acetate only 438 54.1
Abiraterone acetate followed by cabazitaxel 10 1.2
Abiraterone acetate followed by docetaxel 50 6.2
Abiraterone acetate followed by enzalutamide 100 12.4
Abiraterone acetate followed by sipuleucel-T 4 0.5
Enzalutamide only 142 17.6
Enzalutamide followed by abiraterone acetate 33 4.1
Enzalutamide followed by abiraterone acetate/enzalutamide* 2 0.2
Enzalutamide followed by cabazitaxel 12 1.5
Enzalutamide followed by docetaxel 15 1.9
Enzalutamide followed by sipuleucel-T 3 0.4
*Abiraterone acetate and enzalutamide treatment were identiﬁed on the same date and reported as a separate treatment
sequence.
Clinical Therapeuticsof patients prescribed either abiraterone acetate or
enzalutamide between September 2012 and March
2014 received only a single line of therapy (72%),
with abiraterone acetate being the most commonly
prescribed ﬁrst-line therapy. Although previous pros-
tate cancer medication use was generally similar
between the abiraterone acetate–treated and
enzalutamide-treated groups, a higher proportion of
ﬁrst-line enzalutamide-treated patients had received0
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Figure 2. Concomitant medication use in the
first line of therapy. LHRH ¼ luteiniz-
ing hormone-releasing hormone.
1822corticosteroids and a prior taxane-based chemother-
apy compared with ﬁrst-line abiraterone acetate–
treated patients. Although this ﬁnding is not surprising
given that during the study period, the indication for
enzalutamide according to the US Food and Drug
Administration approval speciﬁed use only in patients
with previous docetaxel treatment, it should be noted
that nearly one half of ﬁrst-line enzalutamide use was
observed in patients who had not received previous
chemotherapy. This ﬁnding, combined with the ob-
servation that an oral treatment was chosen as the
second-line treatment in the majority of patients
receiving a second-line agent, may be an indicator of
patient or physician preference for oral-based thera-
pies versus existing chemotherapy strategies. This
ﬁnding may also be due, at least in part, to patient
preferences for more convenient oral treatments.17
Docetaxel was the only therapy available to treat
mCRPC up until 2010, but the changing landscape of
prostate cancer treatment with the addition of novel
therapies has increased overall survival in patients
with mCRPC from an average of 6 to 10 months to a
new average of 18 to 24 months.18 Due to this
evolving treatment landscape, treatment sequencing
has not yet been well deﬁned.19,20 Ongoing trials are
resulting in updated package labeling expanding the
indications for existing therapies. Physicians andVolume 38 Number 8
E. Malangone-Monaco et al.patients will need to consider a multitude of factors
aside from survival beneﬁt, including adverse events,
contraindications, and patient preference, when
choosing which treatment to initiate ﬁrst-line and
which treatments to use after progression.
This study is subject to several limitations. First, the
oncology EMR database contains only health care
services provided inside the oncologist’s ofﬁce.
Medical records for services provided outside the
oncologist’s ofﬁce may not be captured in the EMR.
In particular, oral medications prescribed or reﬁlled
outside of the oncologist’s ofﬁce may be missing. For
example, the rate of concurrent corticosteroid use
during ﬁrst-line abiraterone acetate treatment (76%)
and during ﬁrst-line enzalutamide treatment (13%)
was lower than recently seen in an analysis of patients
with prostate cancer in 3 claims databases.21 In the
claims database analysis, concurrent ﬁrst-line cortico-
steroid use ranged from 81% to 86% and 32% to
38% for abiraterone acetate–treated patients and
enzalutamide-treated patients, respectively. Second,
abiraterone acetate, enzalutamide, docetaxel, cabazi-
taxel, and sipuleucel-T were the only treatments
assessed in this analysis. To better understand the
utilization of other mCRPC treatments, various
potential concurrent medications such as hormone
therapy (LHRH agonists, LHRH antagonists, antian-
drogens, and diethylstilbestrol), corticosteroids, and
other biologic and chemotherapy treatments were
assessed in the pre-index period and during the ﬁrst
line of therapy. Standard comorbidities and clinical
characteristics, as well as observations about patient
disposition, may be missing from the EMR database.
Oncologists may not record comorbidities in the
EMR that do not affect treatment decisions. Clinical
information about mortality was not captured. Longer
follow-up may have provided insights regarding sec-
ond and subsequent lines of therapy. Finally, because
indications for PC treatments have been expanding
over time, this study may not reﬂect the most current
prescribing patterns.CONCLUSIONS
This study provides an initial description of real-world
treatment sequencing patterns in patients with
advanced prostate cancer treated with drugs typically
used in the mCRPC setting. As indications for
mCRPC treatments expand over time, this studyAugust 2016should be re-visited with additional longitudinal data
as the treatment landscape continues to evolve.ACKNOWLEDGMENTS
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